Humacyte, Inc. 8-K

What Happened

• On June 10, 2026, Humacyte, Inc. announced the presentation of results from its Phase 3 clinical trial (V012) of the acellular tissue engineered vessel (ATEV) for arteriovenous access in female patients with end‑stage renal disease requiring hemodialysis. The company filed a press release (Exhibit 99.1) and made an investor presentation available (Exhibit 99.2) in the Form 8‑K.

Key Details

• Date of announcement: June 10, 2026.
• Trial: Phase 3 V012, evaluating ATEV in arteriovenous access for female ESRD patients on hemodialysis.
• Materials filed with the 8‑K: press release (Exhibit 99.1) and investor presentation (Exhibit 99.2).
• The filing does not include financial statements or other operational disclosures beyond these materials.

Why It Matters

• Phase 3 data are major clinical milestones; publishing and presenting V012 results provides investors with new information about Humacyte’s lead product candidate and its performance in a defined patient subgroup.
• The investor presentation and press release give the market a chance to assess clinical progress, which can influence investor sentiment, potential regulatory discussions, and commercial outlook depending on the data content.
• Investors should review the attached press release and presentation for details on outcomes, safety, and next steps the company outlines.